Cargando…

C26-Ceramide as highly sensitive biomarker for the diagnosis of Farber Disease

Farber disease (FD) is a rare autosomal recessive disease caused by mutations in the acid ceramidase gene (ASAH1). Low ceramidase activity results in the accumulation of fatty substances, mainly ceramides. Hallmark symptoms at clinical level are periarticular nodules, lipogranulomas, swollen and pai...

Descripción completa

Detalles Bibliográficos
Autores principales: Cozma, Claudia, Iurașcu, Marius-Ionuț, Eichler, Sabrina, Hovakimyan, Marina, Brandau, Oliver, Zielke, Susanne, Böttcher, Tobias, Giese, Anne-Katrin, Lukas, Jan, Rolfs, Arndt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522391/
https://www.ncbi.nlm.nih.gov/pubmed/28733637
http://dx.doi.org/10.1038/s41598-017-06604-2
_version_ 1783252157555802112
author Cozma, Claudia
Iurașcu, Marius-Ionuț
Eichler, Sabrina
Hovakimyan, Marina
Brandau, Oliver
Zielke, Susanne
Böttcher, Tobias
Giese, Anne-Katrin
Lukas, Jan
Rolfs, Arndt
author_facet Cozma, Claudia
Iurașcu, Marius-Ionuț
Eichler, Sabrina
Hovakimyan, Marina
Brandau, Oliver
Zielke, Susanne
Böttcher, Tobias
Giese, Anne-Katrin
Lukas, Jan
Rolfs, Arndt
author_sort Cozma, Claudia
collection PubMed
description Farber disease (FD) is a rare autosomal recessive disease caused by mutations in the acid ceramidase gene (ASAH1). Low ceramidase activity results in the accumulation of fatty substances, mainly ceramides. Hallmark symptoms at clinical level are periarticular nodules, lipogranulomas, swollen and painful joints and a hoarse voice. FD phenotypes are heterogeneous varying from mild to very severe cases, with the patients not surviving past their first year of life. The diagnostic aspects of FD are poorly developed due to the rarity of the disease. In the present study, the screening for ceramides and related molecules was performed in Farber affected patients (n = 10), carriers (n = 11) and control individuals (n = 192). This study has the highest number of enrolled Farber patients and carriers reported to present. Liquid chromatography multiple reaction mass spectrometry (LC/MRM-MS) studies revealed that the ceramide C26:0 and especially its isoform 1 is a highly sensitive and specific biomarker for FD (p < 0.0001). The new biomarker can be determined directly in the dried blood spot extracts with low sample consumption. This allows for easy sample preparation, high reproducibility and use in high throughput screenings.
format Online
Article
Text
id pubmed-5522391
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-55223912017-07-26 C26-Ceramide as highly sensitive biomarker for the diagnosis of Farber Disease Cozma, Claudia Iurașcu, Marius-Ionuț Eichler, Sabrina Hovakimyan, Marina Brandau, Oliver Zielke, Susanne Böttcher, Tobias Giese, Anne-Katrin Lukas, Jan Rolfs, Arndt Sci Rep Article Farber disease (FD) is a rare autosomal recessive disease caused by mutations in the acid ceramidase gene (ASAH1). Low ceramidase activity results in the accumulation of fatty substances, mainly ceramides. Hallmark symptoms at clinical level are periarticular nodules, lipogranulomas, swollen and painful joints and a hoarse voice. FD phenotypes are heterogeneous varying from mild to very severe cases, with the patients not surviving past their first year of life. The diagnostic aspects of FD are poorly developed due to the rarity of the disease. In the present study, the screening for ceramides and related molecules was performed in Farber affected patients (n = 10), carriers (n = 11) and control individuals (n = 192). This study has the highest number of enrolled Farber patients and carriers reported to present. Liquid chromatography multiple reaction mass spectrometry (LC/MRM-MS) studies revealed that the ceramide C26:0 and especially its isoform 1 is a highly sensitive and specific biomarker for FD (p < 0.0001). The new biomarker can be determined directly in the dried blood spot extracts with low sample consumption. This allows for easy sample preparation, high reproducibility and use in high throughput screenings. Nature Publishing Group UK 2017-07-21 /pmc/articles/PMC5522391/ /pubmed/28733637 http://dx.doi.org/10.1038/s41598-017-06604-2 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Cozma, Claudia
Iurașcu, Marius-Ionuț
Eichler, Sabrina
Hovakimyan, Marina
Brandau, Oliver
Zielke, Susanne
Böttcher, Tobias
Giese, Anne-Katrin
Lukas, Jan
Rolfs, Arndt
C26-Ceramide as highly sensitive biomarker for the diagnosis of Farber Disease
title C26-Ceramide as highly sensitive biomarker for the diagnosis of Farber Disease
title_full C26-Ceramide as highly sensitive biomarker for the diagnosis of Farber Disease
title_fullStr C26-Ceramide as highly sensitive biomarker for the diagnosis of Farber Disease
title_full_unstemmed C26-Ceramide as highly sensitive biomarker for the diagnosis of Farber Disease
title_short C26-Ceramide as highly sensitive biomarker for the diagnosis of Farber Disease
title_sort c26-ceramide as highly sensitive biomarker for the diagnosis of farber disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522391/
https://www.ncbi.nlm.nih.gov/pubmed/28733637
http://dx.doi.org/10.1038/s41598-017-06604-2
work_keys_str_mv AT cozmaclaudia c26ceramideashighlysensitivebiomarkerforthediagnosisoffarberdisease
AT iurascumariusionut c26ceramideashighlysensitivebiomarkerforthediagnosisoffarberdisease
AT eichlersabrina c26ceramideashighlysensitivebiomarkerforthediagnosisoffarberdisease
AT hovakimyanmarina c26ceramideashighlysensitivebiomarkerforthediagnosisoffarberdisease
AT brandauoliver c26ceramideashighlysensitivebiomarkerforthediagnosisoffarberdisease
AT zielkesusanne c26ceramideashighlysensitivebiomarkerforthediagnosisoffarberdisease
AT bottchertobias c26ceramideashighlysensitivebiomarkerforthediagnosisoffarberdisease
AT gieseannekatrin c26ceramideashighlysensitivebiomarkerforthediagnosisoffarberdisease
AT lukasjan c26ceramideashighlysensitivebiomarkerforthediagnosisoffarberdisease
AT rolfsarndt c26ceramideashighlysensitivebiomarkerforthediagnosisoffarberdisease